Development of Radio-Imaging Agents Targeting Necroptosis

The joint-effort project by Nordion Inc and the University of Ottawa Heart Institute aims to develop a series of radiolabeled necrostatin derivatives, which act as imaging agents based on necroptosis (programmed necrosis - a type of cell death) inhibitors to help diagnose disease (such as cardiovascular, neurological diseases and cancer) and monitor their treatment effects. The roles of the fellow are to design, synthesize and characterize these agents and to assist in testing their biological properties through further in vitro and in vivo evaluation. The success of the proposed research will also benefit Nordion by strengthening its R&D capacity and adding potential new products to its innovation pipeline.

Intern: 
Wei Gan
Superviseur universitaire: 
Dr. Terrence Ruddy
Project Year: 
2014
Province: 
Ontario
Université: 
Partenaire: 
Discipline: 
Programme: